(Q43953684)

28 November 2017

title

Renal cell carcinoma may adapt to and overcome anti-angiogenic intervention with thalidomide (English)

1 reference

28 November 2017

0 references

angiogenesis inhibitor

1 reference

1 reference

Douglas ML

1

1 reference

28 November 2017

Reid JL

2

1 reference

28 November 2017

Hii SI

3

1 reference

28 November 2017

Jonsson JR

4

1 reference

28 November 2017

Nicol DL

5

1 reference

28 November 2017

publication date

1 April 2002

1 reference

28 November 2017

1 reference

28 November 2017

volume

89

1 reference

28 November 2017

issue

6

1 reference

28 November 2017

page(s)

591-595

1 reference

Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1046/J.1464-410X.2002.02666.X

Effects of Thalidomide and Related Metabolites in a Mouse Corneal Model of Neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1464-410X.2002.02666.X

Mechanism of action in thalidomide teratogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1464-410X.2002.02666.X

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1464-410X.2002.02666.X

Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1464-410X.2002.02666.X

Angiogenesis activators and inhibitors differentially regulate caveolin-1 expression and caveolae formation in vascular endothelial cells. Angiogenesis inhibitors block vascular endothelial growth factor-induced down-regulation of caveolin-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1464-410X.2002.02666.X

Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1464-410X.2002.02666.X

Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate–Phenol–Chloroform Extraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1464-410X.2002.02666.X

Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1464-410X.2002.02666.X

Myoblast alpha v beta3 integrin levels are controlled by transcriptional regulation of expression of the beta3 subunit and down-regulation of beta3 subunit expression is required for skeletal muscle cell differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1464-410X.2002.02666.X

Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1046/J.1464-410X.2002.02666.X

10.1046/J.1464-410X.2002.02666.X

21 January 2018

Identifiers

DOI

1 reference

28 November 2017

1 reference